Advanced Semantic Knowledge-Based Bio-Medical Search Solution

A web browser that can understand technical terms in life sciences and automatically find additional resources and services has been developed by European researchers. It could lead to a new generation of intelligent search engines. The life sciences community has built numerous databases - such as for gene sequencing and information about diseases - that are available to researchers as 'grid' services.

"Grid computing is essentially about building virtual organisations that are independent of the physical location where they reside," says Michael Schroeder of Technische Universität Dresden.

The problem is how to link those services to other scientific information found on the web. Schroeder is coordinator of the EU-funded Sealife project which has created a 'semantic grid browser' to make grid services for the life sciences much more accessible.

"We have the web on the one hand and then we have grid computing, with its many services, on the other," he says. "A semantic grid browser seamlessly integrates them.

"It tries to understand what it finds on web pages, interprets this content and then links it, on the fly, to services that might be useful to the user."

The key to the Sealife browser is a 'semantic hyperlink' that shows up on the page to direct users to relevant services. The link is not put there by the website but by the browser itself.

How does it do that?
First, the browser needs to understand the content of the page and identify terms which could be linked to grid services. An example tested in the Sealife project is the naming of genes. Each human gene has an average of 5.5 names, Schroeder points out, but if it can be identified correctly, a link can be made to a wealth of information about that gene.

The browser must also be able to handle ambiguity. "If I see 'Jaguar' on a web page, what is it? Is it an animal? Is it a car? Is it the Mac operating system?" Sealife uses specialised algorithms to work out the context from other words on the page and correctly interpret the meaning.

It is still not an exact science, though. The Sealife team entered their algorithm in an international competition with 50 others to identify names of genes. They won, with an 81% success rate, though Schroeder says they have now got that up to 87%.

Background knowledge
The second challenge is the background knowledge that allows the browser to make sense of the identified terms. Such knowledge is formally known as an 'ontology', a systematic hierarchy of concepts and their relation to one another. Biology, with its extensive taxonomies, is an ideal field for semantic grid browsing.

"All these efforts of building hierarchical classification systems have been at the core of biology for centuries," says Schroeder. "Biologists are used to it and there are many efforts to make information exchangeable."

But outside the life sciences such systematic classification is not so well developed, and the Sealife project has created editors to build ontologies from published literature in any specific field of interest.

"We developed algorithms that grind through this data, identify the key concepts and then the ontology editor offers these concepts to you," Schroeder explains. "If you agree, it then searches the web to find things that look like definitions. This whole process of building this background knowledge cannot be fully automated but you can ease the pain of doing this quite significantly."

Different varieties of the Sealife browser build on work by partners in Edinburgh, Manchester, London and Sophia-Antipolis, as well as in Dresden. They have been tested in three scenarios: evidence-based medicine, mining of scientific and patent literature, and in molecular biology. In each case, the focus has been on infectious diseases.

Browser that understands everything?
So successful has the project been that TU Dresden has spun-off a new company, Transinsight, to exploit work done in Sealife. The company has sold semantic browsers to such major customers as BASF and Unilever and runs the GoPubMed search engine, which is linked to the respected PubMed archive of biomedical literature.

But there is no reason why a semantic browser should be confined to specialised academic areas. Could we have a browser that understands everything? Schroeder thinks that is not as far-fetched as it may seem. "The vision is to include every domain," he says. "For example, if we were able to extract and formalise the knowledge in Wikipedia we would have this general background knowledge that covers all areas."

Many researchers look forward to a next-generation search engine that can understand what the user is looking for and return much more relevant results than today's engines can. "This will involve integrating information," says Schroeder, "because very often answers to questions are not provided in one document as a single statement that I can pick up by keywords.

"In the future, we will need background knowledge and this is at the core of Sealife. If we build semantic into search, and make it scaleable, then you will have the next-generation search engine."

The Sealife project received funding from the ICT strand of the EU's Sixth Framework Programme for research.

For further infoprmation, please visit:

Source: ICT Results

About Transinsight
Transinsight is focused on semantic software solutions in the area of knowledge- and meaning-based computing. The flagship product, GoPubMed PRO, a semantic biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. The enterprise is headquartered in Dresden, Germany. Transinsight is ranked under the Top 5 biotech companies in Europe.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...